Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Updated two-year overall survival and toxicity outcomes of BCMA CAR-T therapy compared with teclistamab in multiple myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJunmin SongJacobi Medical CenterWLW LiJacobi Medical CenterYLYue LiJacobi Medical Center

Discussion

Loading...

Member takes

Implication

Retrospective cohort study compares two-year overall survival outcomes in multiple myeloma, suggesting CAR-T offers better survival despite higher toxicity.

Key Points

  • This study aims to evaluate the two-year overall survival and toxicity outcomes of BCMA CAR-T therapy compared with teclistamab in patients with multiple myeloma.
  • Conducted a retrospective cohort study using the TriNetX US Collaborative Network data from over 70 healthcare institutions.
  • Patients treated between 2021 and 2023 with either CAR-T therapy or teclistamab were included, excluding other bispecific antibodies.
  • Propensity score matching was performed to balance baseline characteristics between the two cohorts.
  • CAR-T therapy showed significantly improved two-year overall survival compared to teclistamab (HR: 0.61, 95% CI: 0.43-0.87, p=0.005).
  • Higher risks of cytokine release syndrome (HR: 1.48, 95% CI: 1.12-1.96, p=0.003) were associated with CAR-T therapy.
  • CAR-T therapy also had elevated risks of immune effector cell-associated neurotoxicity syndrome (HR: 2.02, 95% CI: 1.20-3.41, p=0.007).

Cite This Study

Song et al. (2026) studied this question.

synapsesocial.com/papers/6a192de6fab5b468c4416cd8https://doi.org/10.1200/jco.2026.44.16_suppl.7527
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations
  2. 2Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort2026 · 1 citations
  3. 3Comparative toxicity profile of chimeric antigen receptor T-cell therapy versus bispecific T-cell engagers in multiple myeloma and B-cell lymphomas: A propensity-matched real-world analysis.2026
  4. 4Abstract 3616: In vivo expansion patterns of anti-BCMA CAR T-cell in relapsed/refractory multiple myeloma: Comparative immunomonitoring of idecabtagene vicleucel and ciltacabtagene autoleucel2024
  5. 5BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma2025